posted by AHIP
on October 15, 2018
WASHINGTON, D.C. – Matt Eyles, president and CEO of America’s Health Insurance Plans (AHIP), issued this statement following the U.S. Patent and Trademark Office (USPTO) final rule, changing the claim construction standard applied during inter partes review (IPR), post-grant review (PGR), and the transitional program for covered business method patents (CBM) proceedings:
Every single American should be able to afford the medications they need. Drug prices are out-of-control, and we must advance policies that increase choice, competition and end this anti-generic patent gaming pursued by Big Pharma.
We are disappointed that the U.S. Patent and Trademark Office (USPTO) final rule will move us further away from these solutions, blocking generic and biosimilar competition and keeping medications expensive and out of reach for millions of Americans and families.
Addressing rising drug prices is an urgent national priority. We will continue to work closely with members of Congress, the administration, and industry stakeholders to identify and advance policies to reduce the burden of high drug prices for American patients and taxpayers.
America’s Health Insurance Plans (AHIP) is the national trade association representing the health insurance community. AHIP’s members provide health and supplemental benefits to millions of Americans through employer-provided coverage, the individual insurance market, and public programs such as Medicare and Medicaid. AHIP advocates for solutions that expand access to affordable health care coverage to all Americans through a competitive marketplace that fosters choice, quality, and innovation. Visit www.ahip.org for more information.